Genefitletics, a biotech and longevity company that offers a system biology + machine learning platform to detect and prevent the onset of metabolic diseases, has entered into the preventive oncology space with the launch of an early detection test of Oral Squamous Cell Carcinoma- ORAONCO. The test, utilising next-generation sequencing and machine learning, measures the functions of oral microbial cells in each patient’s saliva and examines interaction between oral microbial activities and mitochondria to discover pre/early molecular features associated with the onset of oral cancer.
The test is built on a vector matrix algorithm which is completely data driven and has been constructed using 5 billion molecular data (nucleotides), phenotype metadata and longitudinal data points specific to Indian adult population with high risk of type 2 diabetes, hypertension and gum diseases and regular consumption of alcohol, tobacco/ tobacco products.
The early detect test statistically combines and quantifies 27 biochemical pathways encompassing seven molecular mechanisms that measure the oral biochemical functions leading to systemic inflammation, oxidative stress and mitochondrial dysfunction to detect the onset of oral cancer at the earliest stage.
The company’s proprietary recommendation engine then constructs and delivers nutritional therapeutics interventions to eliminate the carcinogenic molecules before cancer cells proliferate and metastasise.
The patients who test positive are told to follow up with a cancer centre/ oncologist for a confirmed diagnosis.
The test aims to equip oncologists with early molecular signs of oral cancer, unidentifiable/not yet reflected in the current biopsy and other screening examinations, empowering them to prevent OSCC, stop its progression or treat it with precision.
The company also equips oncologists with a unique cocktail approach that blends carcinogenic molecular eliminating therapeutics with standard of care cancer therapies to prevent the recurrence and improve the effectiveness of the therapies.
The current standard of care for oral cancer is primitive, and most clinicians rely on physical examinations of the mouth to identify lesions or breath tests, which could also turn out to be false positives. This outdated approach is the core reason why oral cancer is detected at a late stage and patients lose on the life-saving treatments.
